A compound of formula: in which: Y at each occurrence is independently selected from N and CH; Y 1 is selected from N and CR 5; wherein R 5 is selected from hydrogen, methoxy and imidazolyl; wherein said imidazolyl is unsubstituted or substituted with methyl; R 1 is a 5 to 9 member heteroaryl ring incorporating one to four nitrogen, oxygen or sulfur atoms, wherein not more than one of the atoms is selected from an oxygen or sulfur; wherein said heteroaryl of R 1 is unsubstituted or substituted with 1 to 3 R 6 groups; R 2 is selected from hydrogen, halo, hydroxy, C 1-4 alkyl, C 1-4 alkoxy, methoxy-carbonyl, 3,6-dihydro-2H-pyran-4-yl, tetrahydro-2H-pyran-4-yl, tetrahydro-2H-pyran-4-yl-oxy and cyclobutyl; wherein said C 1-4 alkyl, C 1-4 alkoxy, cyclobutyl or tetrahydro-2H-pyran-4-yl of R 2 can be unsubstituted or substituted with 1 to 3 groups independently selected from halo, hydroxy, cyano, C 1-4 alkoxy, morpholino, piperazinyl and NR 5a R 5b; wherein R 5a is selected from hydrogen and C 1-4 alkyl; and R 5b is selected from hydroxy-ethyl; wherein said piperazinyl substituent of R 2 can be unsubstituted or further substituted with C 1-4 alkyl; R 3 is selected from hydrogen and halo; R 4 is selected from -SF 5 and -Y 2 -CF 2 -Y 3; R 6 at each occurrence is independently selected from hydrogen, hydroxy, C 1-4 alkyl, C 1-4 alkoxy, cyano, trifluoromethyl, halo, amino, methyl-carbonyl, methoxy-carbonyl, cyclopropyl and pyrrolidinyl-methyl; wherein said C 1-4 alkyl or C 1-4 alkoxy of R 6 is unsubstituted or substituted with 1 to 3 groups independently selected from halo and hydroxy; Y 2 is selected from CF 2, O and S 0-2; and Y 3 is selected from hydrogen, halo, methyl, difluoromethyl and trifluoromethyl; Y 4 is selected from N and CR 2; Y 5 and Y 6 are independently selected from N, CR 5 or CF; wherein R 5 is selected from hydrogen and halo; with the proviso that when Y 4 is N, Y 5, Y 6 and Y 1 are each CR 5; or the pharmaceutically acceptable salts thereof; with the proviso that the compounds of formula I do not include 3-(2-aminoquinazolin-6-yl)-4-methyl-N-(4-(trifluoromethoxy)phenyl)-benzamide and 3-(2-aminoquinazolin-6-yl)-5-bromo-N-(4-(trifluoromethoxy)phenyl)-benzamide, for use in the treatment of cancer, a virus infection selected from a Pox virus and an Ebola virus infection or a c-ABL mediated CNS disorder selected from Alzheimer's and Pick disease. Y at each occurrence is independently selected from N and CH; Y 1 is selected from N and CR 5; wherein R 5 is selected from hydrogen, methoxy and imidazolyl; wherein said imidazolyl is unsubstituted or substituted with methyl; R 1 is a 5 to 9 member heteroaryl ring incorporating one to four nitrogen, oxygen or sulfur atoms, wherein not more than one of the atoms is selected from an oxygen or sulfur; wherein said heteroaryl of R 1 is unsubstituted or substituted with 1 to 3 R 6 groups; R 2 is selected from hydrogen, halo, hydroxy, C 1-4 alkyl, C 1-4 alkoxy, methoxy-carbonyl, 3,6-dihydro-2H-pyran-4-yl, tetrahydro-2H-pyran-4-yl, tetrahydro-2H-pyran-4-yl-oxy and cyclobutyl; wherein said C 1-4 alkyl, C 1-4 alkoxy, cyclobutyl or tetrahydro-2H-pyran-4-yl of R 2 can be unsubstituted or substituted with 1 to 3 groups independently selected from halo, hydroxy, cyano, C 1-4 alkoxy, morpholino, piperazinyl and NR 5a R 5b; wherein R 5a is selected from hydrogen and C 1-4 alkyl; and R 5b is selected from hydroxy-ethyl; wherein said piperazinyl substituent of R 2 can be unsubstituted or further substituted with C 1-4 alkyl; R 3 is selected from hydrogen and halo; R 4 is selected from -SF 5 and -Y 2 -CF 2 -Y 3; R 6 at each occurrence is independently selected from hydrogen, hydroxy, C 1-4 alkyl, C 1-4 alkoxy, cyano, trifluoromethyl, halo, amino, methyl-carbonyl, methoxy-carbonyl, cyclopropyl and pyrrolidinyl-methyl; wherein said C 1-4 alkyl or C 1-4 alkoxy of R 6 is unsubstituted or substituted with 1 to 3 groups independently selected from halo and hydroxy; Y 2 is selected from CF 2, O and S 0-2; and Y 3 is selected from hydrogen, halo, methyl, difluoromethyl and trifluoromethyl; Y 4 is selected from N and CR 2; Y 5 and Y 6 are independently selected from N, CR 5 or CF; wherein R 5 is selected from hydrogen and halo; with the proviso that when Y 4 is N, Y 5, Y 6 and Y 1 are each CR 5; or the pharmaceutically acceptable salts thereof; with the proviso that the compounds of formula I do not include 3-(2-aminoquinazolin-6-yl)-4-methyl-N-(4-(trifluoromethoxy)phenyl)-benzamide and 3-(2-aminoquinazolin-6-yl)-5-bromo-N-(4-(trifluoromethoxy)phenyl)-benzamide, for use in the treatment of cancer, a virus infection selected from a Pox virus and an Ebola virus infection or a c-ABL mediated CNS disorder selected from Alzheimer's and Pick disease.